tetano
Editor, Senior Moderator
J Clin Med
. 2022 Dec 15;11(24):7452.
doi: 10.3390/jcm11247452.
Assessing the Efficacy of Early Therapies against SARS-CoV-2 in Hematological Patients: A Real-Life Study from a COVID-19 Referral Centre in Northern Italy
Marta Colaneri[SUP] 1 [/SUP], Teresa Chiara Pieri[SUP] 1 [/SUP], Silvia Roda[SUP] 1 [/SUP], Alessandra Ricciardi[SUP] 1 [/SUP], Manuel Gotti[SUP] 2 [/SUP], Jacqueline Ferrari[SUP] 2 [/SUP], Luca Arcaini[SUP] 2 3 [/SUP], Sara Rattotti[SUP] 2 [/SUP], Antonio Piralla[SUP] 4 [/SUP], Federica Giardina[SUP] 4 [/SUP], Guglielmo Ferrari[SUP] 4 [/SUP], Paolo Sacchi[SUP] 1 [/SUP], Valentina Zuccaro[SUP] 1 [/SUP], Fausto Baldanti[SUP] 5 4 [/SUP], Raffaele Bruno[SUP] 5 1 [/SUP]
Affiliations
Abstract
Early therapies to prevent severe COVID-19 have an unclear impact on patients with hematological malignancies. The aim of this study was to assess their efficacy in this group of high-risk patients with COVID-19 in preventing hospitalizations and reducing the SARS-CoV-2 shedding. This was a single-center, retrospective, observational study conducted in the Fondazione IRCSS Policlinico San Matteo of Pavia, Northern Italy. We extracted the data of patients with hematologic malignancies and COVID-19 who received and did not receive early COVID-19 treatment between 23 December 2021, and May 2022. We used a Cox proportional hazard model to assess whether receiving any early treatment was associated with lower rates of hospitalization and reduced viral shedding. Data from 88 patients with hematologic malignancies were extracted. Among the patients, 55 (62%) received any early treatment, whereas 33 (38%) did not. Receiving any early therapy did not significantly reduce the hospitalization rate in patients with hematologic malignancies (HR 0.51; SE 0.63; p-value = 0.28), except in the vaccinated non-responders subgroup of patients with negative anti SARS-CoV-2 antibodies at the time of infection, who benefited from early therapies against SARS-CoV-2 (HR 0.07; SE 1.04; p-value = 0.001). Moreover, no difference on viral load decay was observed. In our cohort of patients with hematologic malignancies infected with SARS-CoV-2, early treatment were not effective in reducing the hospitalization rate due to COVID-19, neither in reducing its viral shedding.
Keywords: COVID-19; early remdesivir; hematological patients; hospitalizations rate; molnupiravir; prolonged viral shedding; ritonavir-boosted nirmatrelvir; sotrovimab.
. 2022 Dec 15;11(24):7452.
doi: 10.3390/jcm11247452.
Assessing the Efficacy of Early Therapies against SARS-CoV-2 in Hematological Patients: A Real-Life Study from a COVID-19 Referral Centre in Northern Italy
Marta Colaneri[SUP] 1 [/SUP], Teresa Chiara Pieri[SUP] 1 [/SUP], Silvia Roda[SUP] 1 [/SUP], Alessandra Ricciardi[SUP] 1 [/SUP], Manuel Gotti[SUP] 2 [/SUP], Jacqueline Ferrari[SUP] 2 [/SUP], Luca Arcaini[SUP] 2 3 [/SUP], Sara Rattotti[SUP] 2 [/SUP], Antonio Piralla[SUP] 4 [/SUP], Federica Giardina[SUP] 4 [/SUP], Guglielmo Ferrari[SUP] 4 [/SUP], Paolo Sacchi[SUP] 1 [/SUP], Valentina Zuccaro[SUP] 1 [/SUP], Fausto Baldanti[SUP] 5 4 [/SUP], Raffaele Bruno[SUP] 5 1 [/SUP]
Affiliations
- PMID: 36556068
- DOI: 10.3390/jcm11247452
Abstract
Early therapies to prevent severe COVID-19 have an unclear impact on patients with hematological malignancies. The aim of this study was to assess their efficacy in this group of high-risk patients with COVID-19 in preventing hospitalizations and reducing the SARS-CoV-2 shedding. This was a single-center, retrospective, observational study conducted in the Fondazione IRCSS Policlinico San Matteo of Pavia, Northern Italy. We extracted the data of patients with hematologic malignancies and COVID-19 who received and did not receive early COVID-19 treatment between 23 December 2021, and May 2022. We used a Cox proportional hazard model to assess whether receiving any early treatment was associated with lower rates of hospitalization and reduced viral shedding. Data from 88 patients with hematologic malignancies were extracted. Among the patients, 55 (62%) received any early treatment, whereas 33 (38%) did not. Receiving any early therapy did not significantly reduce the hospitalization rate in patients with hematologic malignancies (HR 0.51; SE 0.63; p-value = 0.28), except in the vaccinated non-responders subgroup of patients with negative anti SARS-CoV-2 antibodies at the time of infection, who benefited from early therapies against SARS-CoV-2 (HR 0.07; SE 1.04; p-value = 0.001). Moreover, no difference on viral load decay was observed. In our cohort of patients with hematologic malignancies infected with SARS-CoV-2, early treatment were not effective in reducing the hospitalization rate due to COVID-19, neither in reducing its viral shedding.
Keywords: COVID-19; early remdesivir; hematological patients; hospitalizations rate; molnupiravir; prolonged viral shedding; ritonavir-boosted nirmatrelvir; sotrovimab.